This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
treatment
Click here for Vydura®▼ (rimegepant) Prescribing Information for Great Britain and Northern Ireland.
Adverse event reporting information can be found at the bottom of the page.
The functional impact of migraine is worsened by more severe pain, more frequent attacks and higher burden in the interictal period (between attacks).1-4
disability
53.7%
of 18,968 people with migraine reported severe impairment or the need for bed rest during a migraine attack.5
53.5%
of 4,022 people with migraine reported significantly reduced involvement or enjoyment in family activities each month.2
32.7%
of 13,061 people with migraine reported that migraine had adversely affected their career.6
32.1%
of 13,061 people with migraine reported worry about long-term financial security. 22.8% reported worry about losing their job.6
50.1%
of 441 people with headaches reported that their colleagues did not accept their headaches.7
Migraine can be associated with many medical comorbidities, occurrence of which may be related to frequency of migraine attacks.8-11
Comorbidities may exacerbate migraine, complicate diagnosis and treatment and increase migraine-related disability.9
The indirect costs of migraine due to work loss and reduced productivity at work are much larger than the direct costs.12,13
Work productivity is reduced for people with migraine versus people without migraine.9,14
Equivalent workdays lost due to absenteeism and presenteeism:15
86 million per year in the UK = 11.4 days per person per year
Based on data from 2016.15
Estimated cost to the UK economy due to absenteeism and presenteeism:15
£5.6 billion - £8.8 billion per year
Based on data from 2016.15
The direct costs of migraine include cost of:12
- pharmaceutical treatments
- diagnostic tests
- primary care appointments
- referral to secondary care
- A&E visits and hospitalisations
It is estimated that the NHS spends around £150 million per year on treating migraine16
In a pathway developed and trialled in Oxfordshire, a headache consultant triages referrals to allow patients with migraine to be diagnosed and treated in the community.
In the 3-month pilot:
-
89% of all headache referrals were directed away from the outpatient department:
- 73% attended community headache clinic
- 11% received written advice
- 5% received imaging without an appointment
- 979 first outpatient neurology appointments were freed up
- Estimated to result in a 65% reduction in outpatient department headache costs over a year (a reduction of £268,000 in Oxfordshire)
Most patients are now seen in the community clinic
94% of patients receive a diagnosis of migraine; 25% are diagnosed with medication overuse headache
81% of patients rated their care in the community clinic as 'excellent' in a satisfaction survey
J Neurol Neurosurg Psychiatry 2010;81(4):428-432
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd.
Pfizer accepts no responsibility for the content or services of the linked site.
PP-PFE-GBR-3858. November 2021
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd.
Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to Pfizer medicines or
business which it has provided or reviewed.
PP-PFE-GBR-3859. November 2021